The adenosinergic system, principally mediated by four subtypes of G-protein-coupled adenosine receptors (A1, A2A, A2B and A3), plays a pivotal role in the regulation of immune responses.

iTeos Therapeutics (ITOS) is gearing up to report results from several of its programs in 2024. I believe that investors can benefit here, because there is potential with multiple shots on goal.

A 1 AR Brain (cortex, hippocampus, cerebellum), spinal cord, eye, adrenal gland, atria, liver, kidney, adipose tissue, salivary glands, esophagus, colon, atrium and ...

Acquires two clinical-stage, best in class adenosine compounds, and two preclinical assets for approximately $21 million upfront consideration Rob Glassman, M.D., Ph.D., director of Tarus and former ...

Portage Biotech, Inc. has announced the re-launch of its subsidiary, Cyncado Therapeutics, which will operate independently to focus on developing adenosine receptor antagonists aimed at improving ...

Perhaps the most intriguing implication of recent breakthrough research lies in an unexpected connection: the most rigorous mechanistic dissection of rapid antidepressant action identifies adenosine ...